Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best mid cap growth stocks to invest in now. Earlier on June 5, Corcept Therapeutics presented detailed results from its Phase 2 DAZALS study of dazucorilant in patients with Amyotrophic Lateral Sclerosis/ALS at the European Network to Cure ALS 2025 annual meeting. While the company announced in December 2024 that DAZALS did not meet its primary endpoint, the presentation highlighted improvement in patient survival.

The DAZALS study was a randomized, double-blind, and placebo-controlled Phase 2 trial that enrolled 249 patients with ALS. These patients were randomized to receive either 150 mg of dazucorilant, 300 mg of dazucorilant, or a placebo daily for 24 weeks. Patients who completed this treatment period were eligible to enroll in a long-term extension study, where all participants received 300 mg of dazucorilant. At week 24 of the study, no deaths occurred in the 83 patients who received 300 mg of dazucorilant, whereas there were 5 deaths in the 82-patient placebo group.

An exploratory analysis at the one-year mark further demonstrated a continued survival benefit, with patients randomized to 300 mg of dazucorilant living significantly longer than those who received placebo and did not switch to dazucorilant in the extension study, which showed a pronounced difference with a hazard ratio of 0.16. Dazucorilant demonstrated an acceptable safety profile throughout the study. ~92% of adverse events were mild to moderate in severity.

Corcept Therapeutics Incorporated (NASDAQ:CORT) discovers and develops medications for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the US.

While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.